【摘要】 目的观察纳米银水凝胶联合α-受体阻滞剂治疗Ⅲ型前列腺炎(慢性前列腺炎/慢性骨盆疼痛综合征,CP/CPPS)的疗效。方法 87例CP/CPPS患者随机分成两组。治疗组44例,给予纳米银水凝胶纳肛,每日1支,15 d为1个疗程,和盐酸特拉唑嗪2 mg口服,每日睡前1次。对照组43例给予盐酸特拉唑嗪2 mg口服,每日睡前1次,另加左氧氟沙星。两组均连用30 d后进行疗效评价。以前列腺炎症状指数评分(NIH-CPSI)作为疗效评价指标,进行统计学分析。结果治疗组显效7例(16%),有效32例(73%),无效5例(11%),总有效率89%。对照组显效4例(9%),有效26例(61%),无效13例(30%),总有效率70%。两组显效率、总有效率比较差异均有统计学意义(P<0.05)。结论纳米银水凝胶联合α-受体阻滞剂治疗CP/CPPS短期临床疗效肯定,长期疗效仍在随访中。纳米银水凝胶较安全,方便,渗透性强,具有抗菌活性,无耐药性和明显毒副作用,值得临床推广应用。更多还原

【Abstract】 Objective To study the therapeutic effectiveness of nanosilver hydrophilic colloid(Bangliean) combined with α-adrenergic receptor antagonists in the treatment of chronic prostatitis / chronic pelvic pain syndrome(CP/CPPS).Methods Eighty-seven patients with CP / CPPS were randomly divided into two groups.Forty-four patients of the treatment group were treated by combination of nanosilver colloid(a piece,once a day,taking by anus)and terazosin(2mg,once a day).Forty-three patients of the control group were treated with Terazosin(2mg,once a day) and levofloxacin(0.2mg,twice a day).After 30 d therapy,all patients in two groups were evaluated respectively by the National Institutes of Health Chronic Prostatitis Symptom Index(NIH-CPSI).Results There were 7(16%) patients with marked effective,32(73%) patients with effective and 5(11%) cases with no effect in treatment group with total effective rate of 89%.In control group,there were 4(9%) patients with marked effective,26(61%)patients with effective and 13(30%)cases with no effect,the total effective rate was 70%.The difference in efficacy between two groups was significant.The obviously effective rate and total effective rate in treatment group(73%,89%)were higher than those in control group(61%,70%,P<0.05).Conclusion Combination of nanosilver hydrophilic colloid and α-adrenergic receptor antagonists has definite effect on the treatment of CP/CPPS.Nanosilver colloid is safe and convenient for treating CP/CPPS,has powerful penetrability and antibacterial properties with no drug-resistance and side-effect.Nanosilver colloid can supersede antibiotic in the treatment of CP/CPPS.更多还原